{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:20:03Z","timestamp":1787800803450,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.bonr.2020.100272","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T02:42:14Z","timestamp":1587609734000},"page":"100272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["What is the relationship between bone turnover markers and skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma? A systematic review and meta-regression analysis"],"prefix":"10.1016","volume":"12","author":[{"given":"Zefei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En-Tzu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Glennane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bonr.2020.100272_bb0005","author":"Amgen, Daiichi Sankyo, Inc"},{"issue":"4","key":"10.1016\/j.bonr.2020.100272_bb0010","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.18388\/abp.2003_3629","article-title":"The roles of annexins and alkaline phosphatase in mineralization process","volume":"50","author":"Balcerzak","year":"2003","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.bonr.2020.100272_bb0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bone.2014.07.036","article-title":"Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study)","volume":"68","author":"Barnadas","year":"2014","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bonr.2020.100272_bb0020","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bonr.2020.100272_bb0025","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bonr.2020.100272_bb0030","series-title":"Systematic Reviews: CRD\u2019s Guidance for Undertaking Reviews in Health Care","author":"Centre for Reviews and Dissemination","year":"2009"},{"issue":"7","key":"10.1016\/j.bonr.2020.100272_bb0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ctrv.2008.05.001","article-title":"Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.bonr.2020.100272_bb0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.bonr.2020.100272_bb0045","first-page":"2587","article-title":"Prostate cancer cells-osteoblast interaction shifts expression of growth\/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts","volume":"9","author":"Fizazi","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bonr.2020.100272_bb0050","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9768","key":"10.1016\/j.bonr.2020.100272_bb0055","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bonr.2020.100272_bb0060","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s12094-016-1590-1","article-title":"SEOM clinical guideline for bone metastases from solid tumours (2016)","volume":"18","author":"Gr\u00e1valos","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"10.1016\/j.bonr.2020.100272_bb0065","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bonr.2020.100272_bb0070","first-page":"335","article-title":"Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States","volume":"7","author":"Hernandez","year":"2015","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.bonr.2020.100272_bb0075","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"10.1016\/j.bonr.2020.100272_bb0080","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"24","key":"10.1016\/j.bonr.2020.100272_bb0085","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bonr.2020.100272_bb0090","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncology"},{"issue":"15","key":"10.1016\/j.bonr.2020.100272_bb0095","doi-asserted-by":"crossref","first-page":"10116","DOI":"10.1200\/JCO.2016.34.15_suppl.10116","article-title":"Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors","volume":"34","author":"Jiang","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bonr.2020.100272_bb0100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"28","key":"10.1016\/j.bonr.2020.100272_bb0105","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bonr.2020.100272_bb0110","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","article-title":"Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity","volume":"12","author":"Lipton","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bonr.2020.100272_bb0115","series-title":"Denosumab for the Prevention of Skeletal-Related Events in Adults with Bone Metastases from Solid Tumours. NICE Technology Appraisal Guidance 265","author":"National Institute for Health and Care Excellence","year":"2012"},{"issue":"6","key":"10.1016\/j.bonr.2020.100272_bb0120","first-page":"755","article-title":"The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain","volume":"19","author":"Pockett","year":"2010","journal-title":"Eur J Cancer Care"},{"issue":"9","key":"10.1016\/j.bonr.2020.100272_bb0125","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/annonc\/mdq037","article-title":"Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer","volume":"21","author":"Rajpar","year":"2010","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.bonr.2020.100272_bb0130","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2001.19.15.3562","article-title":"Biology of osteoclast activation in cancer","volume":"19","author":"Roodman","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.bonr.2020.100272_bb0135","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bonr.2020.100272_bb0140","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"issue":"16","key":"10.1016\/j.bonr.2020.100272_bb0145","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic acid lung cancer and other solid tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.bonr.2020.100272_bb0150","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"35","key":"10.1016\/j.bonr.2020.100272_bb0155","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bonr.2020.100272_bb0160","author":"Sweeney"},{"key":"10.1016\/j.bonr.2020.100272_bb0165","author":"Swiss Group for Clinical Cancer Research"},{"issue":"3","key":"10.1016\/j.bonr.2020.100272_bb0170","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bonr.2020.100272_bb0175","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/clinchem\/45.8.1359","article-title":"Clinical utility of biochemical markers of bone remodeling","volume":"45","author":"Watts","year":"1999","journal-title":"Clin. Chem."},{"issue":"14","key":"10.1016\/j.bonr.2020.100272_bb0180","first-page":"5652","article-title":"Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway","volume":"61","author":"Yang","year":"2001","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bonr.2020.100272_bb0185","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ejca.2010.12.004","article-title":"Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases","volume":"47","author":"Zhao","year":"2011","journal-title":"Eur. J. Cancer"}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187220300322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187220300322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:23:34Z","timestamp":1762446214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187220300322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":37,"alternative-id":["S2352187220300322"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2020.100272","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the relationship between bone turnover markers and skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma? A systematic review and meta-regression analysis","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2020.100272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100272"}}